Relation of serum uric acid levels to readmission and mortality in patients with heart failure.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 10 2023
28 10 2023
Historique:
received:
17
05
2023
accepted:
21
10
2023
medline:
30
10
2023
pubmed:
29
10
2023
entrez:
29
10
2023
Statut:
epublish
Résumé
Data on the association between uric acid (UA) levels and clinical outcomes, such as readmission and mortality, in patients with heart failure are scarce. This study explores whether UA exhibits an independent association with the composite endpoint (clinical outcome during 6 months after discharge, including mortality and 6-month readmission) in patients with chronic heart failure while controlling for other covariates. This study was an observational retrospective study. A cohort of 1943 consecutive patients diagnosed with chronic heart failure, who were admitted between December 2016 and June 2019, was included in the study. Data were sourced from PhysioNet. The independent variable analyzed was the UA level, and the dependent variable was a composite endpoint comprising mortality and 6-month readmission. The study had 1943 participants, of which 91.04% were aged more than 60 years and 58.05% were female. The fully-adjusted model yielded a positive correlation between UA levels (per 10 µmol/L) and the composite endpoint as well as readmission, following adjustment for confounding variables (HR = 1.01, 95% CI 1.00-1.01). Notably, a non-linear relationship was observed between UA levels and the composite endpoint, particularly readmission, with a J-shaped correlation observed between UA levels and both the composite endpoint and readmission. Overall, we found that the serum UA levels at admission were independently and positively associated with the risk of the composite endpoint (clinical outcomes during 6 months after discharge), especially readmission after adjusting other covariates. A J-shaped relationship was observed between UA levels and the composite endpoint and readmission.
Identifiants
pubmed: 37898627
doi: 10.1038/s41598-023-45624-z
pii: 10.1038/s41598-023-45624-z
pmc: PMC10613251
doi:
Substances chimiques
Uric Acid
268B43MJ25
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18495Informations de copyright
© 2023. The Author(s).
Références
Front Pharmacol. 2020 Nov 16;11:582680
pubmed: 33304270
Intern Emerg Med. 2014 Sep;9(6):655-60
pubmed: 24214336
Eur Cardiol. 2016 Aug;11(1):54-59
pubmed: 30310447
Clin Cardiol. 2013 Feb;36(2):110-6
pubmed: 23335377
JAMA. 2023 Mar 14;329(10):827-838
pubmed: 36917048
Am J Cardiol. 2020 Mar 1;125(5):772-776
pubmed: 31898963
Lancet. 2017 Oct 28;390(10106):1981-1995
pubmed: 28460827
Atherosclerosis. 2020 Mar;297:40-46
pubmed: 32062138
J Card Fail. 2020 Nov;26(11):968-976
pubmed: 32652245
Circulation. 2000 Jun 13;101(23):E215-20
pubmed: 10851218
Am J Cardiol. 2020 Jul 15;127:64-72
pubmed: 32386813
Can J Diabetes. 2015 Jun;39(3):239-46
pubmed: 25600084
Circulation. 2022 Jan 11;145(2):110-121
pubmed: 34743555
Nutr Metab (Lond). 2021 Dec 20;18(1):107
pubmed: 34930343
J Hypertens. 2021 Jan;39(1):62-69
pubmed: 32694342
Congest Heart Fail. 2011 Mar-Apr;17(2):80-4
pubmed: 21449996
Intern Emerg Med. 2019 Sep;14(6):949-956
pubmed: 30864092
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Mediators Inflamm. 2016;2016:8603164
pubmed: 28070145
Sci Data. 2021 Feb 5;8(1):46
pubmed: 33547290
Korean J Intern Med. 2010 Sep;25(3):253-9
pubmed: 20830221
Int J Cardiol. 2016 Jun 15;213:4-7
pubmed: 26341316
Nat Rev Dis Primers. 2020 Mar 5;6(1):16
pubmed: 32139695